Cargando…
CDK4/6 inhibition triggers anti-tumor immunity
Cyclin-dependent kinases 4 and 6 (CDK4/6) are fundamental drivers of the cell cycle and are required for the initiation and progression of various malignancies(1,2). Pharmacologic inhibitors of CDK4/6 have shown significant activity against several solid tumors(3,4). Their primary mechanism of actio...
Autores principales: | Goel, Shom, DeCristo, Molly J., Watt, April C., BrinJones, Haley, Sceneay, Jaclyn, Li, Ben B., Khan, Naveed, Ubellacker, Jessalyn M., Xie, Shaozhen, Metzger-Filho, Otto, Hoog, Jeremy, Ellis, Matthew J., Ma, Cynthia, Ramm, Susanne, Krop, Ian E., Winer, Eric P., Roberts, Thomas M., Kim, Hye-Jung, McAllister, Sandra S., Zhao, Jean J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570667/ https://www.ncbi.nlm.nih.gov/pubmed/28813415 http://dx.doi.org/10.1038/nature23465 |
Ejemplares similares
-
Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells
por: Ubellacker, Jessalyn M., et al.
Publicado: (2017) -
The unresolved role of systemic factors in bone metastasis
por: Ubellacker, Jessalyn M., et al.
Publicado: (2016) -
Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer
por: Watt, April C., et al.
Publicado: (2022) -
CDK4/6 inhibition in breast cancer: current practice and future
directions
por: Pernas, Sonia, et al.
Publicado: (2018) -
Accounting for tumor heterogeneity when using CRISPR-Cas9 for cancer progression and drug sensitivity studies
por: Olive, Jessica F., et al.
Publicado: (2018)